{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:58:52Z","timestamp":1785484732784,"version":"3.56.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"name":"UCLA SPORE in Prostate Cancer","award":["P50 CA092131"],"award-info":[{"award-number":["P50 CA092131"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Liquid biopsies using cell-free DNA (cfDNA) can identify actionable somatic alterations in prostate cancer (PCa). The presence of alterations related to clonal hematopoiesis (CH) can complicate interpretation of cfDNA results and lead to clinical inaction. We sought to determine alteration profiles identified by cfDNA testing in a large, racially diverse cohort of United States Veterans with metastatic PCa and quantify the extent of CH interference in the identification of actionable alterations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Next-generation sequencing of cfDNA biopsy specimens from US Veterans with metastatic PCa was performed using Foundation Medicine through the VA National Precision Oncology Program (NPOP) from August 2020 to January 2025. Actionable and non-actionable alteration rates were compared between tests with and without identification of a CH alteration. Tests with CH interference were then stratified by the presence of a PCa-related alteration (TMPRSS2, ERG, SPOP) and rates of actionable and non-actionable alterations were compared between these groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>cfDNA alterations were identified in 2501\/2657 (94.1%) cfDNA tests. CH interference was common, with 663\/2657 (25%) tests identifying CH alterations only and 1615\/2657 (60.8%) tests identifying CH and non-CH alterations concurrently. Accounting for tests in which no alteration was identified (156\/2657; [5.9%]), only 223\/2501 (8.4%) tests exhibited non-CH only alterations. Alteration rates in FDA-approved targetable genes were similar in samples with and without CH interference, except for CDK12 variants, which were more frequently identified in tests without CH interference (8.5% vs 3.8%, P\u2009&amp;lt;\u2009.01) and BRCA1 variants which were more frequently identified in tests with CH interference (2.0% vs 0%, P\u2009=\u2009.02). In samples with CH interference, alterations in PTEN, RB1, and TP53 were more likely and homologous recombination repair (HRR) alterations were less likely in samples with a PCa specific alteration versus those without (tumor suppressor gene 72% vs 51%, P\u2009&amp;lt;\u2009.0001; HRR 36% vs 56%, P\u2009&amp;lt;\u2009.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CH interference was very common in cfDNA testing in metastatic PCa patients. The absence of a CH alteration or presence of a known PCa-related alteration does not reliably modify identification frequencies of actionable alterations. Robust CH inferential platforms or analysis of a matched lymphocyte sample with cfDNA may improve clinical differentiation of CH versus PCa-derived cfDNA results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag265","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:28:03Z","timestamp":1784633283000},"source":"Crossref","is-referenced-by-count":0,"title":["Interference of clonal hematopoiesis in cfDNA liquid biopsy testing and identification of actionable alterations in large diverse cohort of US veterans"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4174","authenticated-orcid":false,"given":"Luca F","family":"Valle","sequence":"first","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System Radiation Oncology Service, , Los Angeles, CA, 90025,","place":["USA"]},{"name":"David Geffen School of Medicine at the University of California Los Angeles Department of Radiation Oncology, , Los Angeles, CA, 90095,","place":["USA"]},{"name":"University of California Los Angeles Jonsson Comprehensive Cancer Center, , Los Angeles, CA, 90095,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Scobie","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs National Oncology Program, , Washington DC, 20420,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs National Oncology Program, , Washington DC, 20420,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin C","family":"Pritchard","sequence":"additional","affiliation":[{"name":"University of Washington Department of Laboratory Medicine, , Seattle, WA, 98195,","place":["USA"]},{"name":"University of Washington Brotman Baty Institute for Precision Medicine, , Seattle, WA, 98195,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-0295","authenticated-orcid":false,"given":"Bruce","family":"Montgomery","sequence":"additional","affiliation":[{"name":"VA Puget Sound Health Care System Medical Oncology Service, , Seattle, WA, 98108,","place":["USA"]},{"name":"University of Washington Division of Oncology, Department of Medicine, , Seattle, WA, 98195,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla P","family":"Garraway","sequence":"additional","affiliation":[{"name":"University of California Los Angeles Jonsson Comprehensive Cancer Center, , Los Angeles, CA, 90095,","place":["USA"]},{"name":"Veterans Affairs Greater Los Angeles Healthcare System Urology Service, , Los Angeles, CA, 90025,","place":["USA"]},{"name":"David Geffen School of Medicine at the University of California Los Angeles Department of Urology, , Los Angeles, CA, 98195,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G","family":"Nickols","sequence":"additional","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System Radiation Oncology Service, , Los Angeles, CA, 90025,","place":["USA"]},{"name":"David Geffen School of Medicine at the University of California Los Angeles Department of Radiation Oncology, , Los Angeles, CA, 90095,","place":["USA"]},{"name":"University of California Los Angeles Jonsson Comprehensive Cancer Center, , Los Angeles, CA, 90095,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-5553","authenticated-orcid":false,"given":"Martin W","family":"Schoen","sequence":"additional","affiliation":[{"name":"Saint Louis VA Medical Center Medical Oncology Service, , St. Louis, MO, 63106,","place":["USA"]},{"name":"St. Louis University Division of Hematology Oncology, Department of Medicine, , St. Louis, MO, 63103,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4836-8483","authenticated-orcid":false,"given":"Amar U","family":"Kishan","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at the University of California Los Angeles Department of Radiation Oncology, , Los Angeles, CA, 90095,","place":["USA"]},{"name":"University of California Los Angeles Jonsson Comprehensive Cancer Center, , Los Angeles, CA, 90095,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-6080","authenticated-orcid":false,"given":"Michael J","family":"Kelley","sequence":"additional","affiliation":[{"name":"Durham Veterans Affairs Health Care System Medical Oncology Service, , Durham, NC, 27705,","place":["USA"]},{"name":"Duke Cancer Institute, Duke University Division of Medical Oncology, Department of Medicine, , Durham, NC, 27708,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B","family":"Rettig","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, Veterans Affairs Greater Los Angeles Healthcare System , Los Angeles, CA, 90025,","place":["USA"]},{"name":"Department of Medicine-Hematology\/Oncology, David Geffen School of Medicine at the University of California Los Angeles , Los Angeles, CA 90095,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-4202","authenticated-orcid":false,"given":"Kara N","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia, PA, 19104,","place":["USA"]},{"name":"Perelman School of Medicine at the University of Pennsylvania, Philadelphia Division of Hematology\/Oncology, Department of Medicine, , PA, 19104,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2026073103163246400_oyag265-B1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.eururo.2020.12.039","article-title":"Genomic testing in patients with metastatic castration-resistant prostate cancer: a pragmatic guide for clinicians","volume":"79","author":"Merseburger","year":"2021","journal-title":"Eur Urol"},{"key":"2026073103163246400_oyag265-B2","doi-asserted-by":"publisher","first-page":"469-","year":"2025","DOI":"10.6004\/jnccn.2025.0052"},{"key":"2026073103163246400_oyag265-B3","doi-asserted-by":"publisher","first-page":"1054497","DOI":"10.3389\/fonc.2022.1054497","article-title":"Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation","volume":"12","author":"Kwan","year":"2022","journal-title":"Front Oncol"},{"key":"2026073103163246400_oyag265-B4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"2026073103163246400_oyag265-B5","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026073103163246400_oyag265-B6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.urolonc.2017.11.017","article-title":"Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA","volume":"36","author":"Ritch","year":"2018","journal-title":"Urol Oncol"},{"key":"2026073103163246400_oyag265-B7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"2026073103163246400_oyag265-B8","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2026073103163246400_oyag265-B9","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"key":"2026073103163246400_oyag265-B10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1200\/PO.20.00144","article-title":"Implications of clonal hematopoiesis for precision oncology","volume":"4","author":"Miller","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2026073103163246400_oyag265-B11","doi-asserted-by":"publisher","first-page":"e2100461","DOI":"10.1200\/PO.21.00461","article-title":"Homologous recombination repair gene variants and outcomes among patients with prostate cancer treated with poly (ADP-ribose) polymerase inhibitors","volume":"6","author":"Price","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026073103163246400_oyag265-B12","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1093\/oncolo\/oyad042","article-title":"Actionable genomic alterations in prostate cancer among black and white United States veterans","volume":"28","author":"Valle","year":"2023","journal-title":"Oncologist"},{"key":"2026073103163246400_oyag265-B13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"2026073103163246400_oyag265-B14","doi-asserted-by":"publisher","first-page":"oyaf049","DOI":"10.1093\/oncolo\/oyaf049","article-title":"Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes","volume":"30","author":"Iranmanesh","year":"2025","journal-title":"Oncologist"},{"key":"2026073103163246400_oyag265-B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27680","article-title":"Clonal hematopoiesis in Gulf war Veterans","volume":"100","year":"2025","journal-title":"Am J Hematol"},{"key":"2026073103163246400_oyag265-B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"2026073103163246400_oyag265-B17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/hmg\/ddac214","article-title":"Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men","volume":"32","author":"Wang","year":"2023","journal-title":"Hum Mol Genet"},{"key":"2026073103163246400_oyag265-B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.9119","article-title":"Somatic tumor next-generation sequencing in US veterans with metastatic prostate cancer","volume":"8","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026073103163246400_oyag265-B19","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00017","article-title":"Identification of actionable genomic alterations using circulating cell-free DNA","volume":"3","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2026073103163246400_oyag265-B20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","article-title":"Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference","volume":"7","author":"Jensen","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026073103163246400_oyag265-B21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"2026073103163246400_oyag265-B22","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jlb.2025.100311","article-title":"Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsy","volume":"9","author":"Brown","year":"2025","journal-title":"J Liq Biopsy"},{"key":"2026073103163246400_oyag265-B23","doi-asserted-by":"publisher","first-page":"e2200261","DOI":"10.1200\/PO.22.00261","article-title":"Tumor fraction correlates with detection of actionable variants across &gt; 23,000 circulating tumor DNA samples","volume":"6","author":"Husain","year":"2022","journal-title":"JCO Precis Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag265\/69696811\/oyag265.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag265\/69696811\/oyag265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag265\/69696811\/oyag265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:16:40Z","timestamp":1785482200000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag265\/8739212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag265","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,8]]},"article-number":"oyag265"}}